Organic first quarter revenue growth of 8.3% in Haleon’s oral health division has helped the group through a weak cold and flu season.
The Sensodyne owner registered organic growth of 2.2% to reach £2.9bn in revenues in the three months to 31 March 2026.
Returning to organic growth in North America, the group “delivered a competitive performance in a challenging market,” according to CEO Brian McNamara.
Overall headwinds from the weak cold and flu season depressed sales by around 1.3 percentage points, according to Haleon’s estimates.
McNamara credited strong performance in the company’s oral health division for its positive Q1 momentum, as innovation and geographic expansion drove double-digit growth in its Sensodyne and Parodontax brands.
“We continue to make progress against our other strategic priorities, with our productivity initiatives driving strong gross margin improvement, supporting our confidence in high single-digit operating profit growth for the year. We are also moving forward on the operating model changes we set out in January, which are designed to drive growth and agility.
“Looking ahead, while we continue to navigate global geopolitical and macroeconomic uncertainties, we expect growth to accelerate across the balance of the year and remain on track to deliver on our full-year guidance.”
Haleon had guided full-year organic revenue growth of 3%-5%, with sequential acceleration through the year, and “high single digit” growth in adjusted operating profit.
No comments yet